Labor Market Pulse · Life Sciences · September 2026
Life Sciences Labor Market Report: Sherman-Denison, TX MSA — September 2026
Sherman stays stable while Texas biomanufacturing pay pulls talent south.
Sherman-Denison's 4.4% unemployment rate and flat job growth contrast with 4.8% statewide manufacturing wage growth concentrated in Houston's biomanufacturing buildout, widening the gap for Sherman-based life sciences employers.
Free archive edition. Published by WageScape as sent to subscribers; data as of September 2026.
Key indicators
- Sherman-Denison unemployment: 4.4% — 12th among Texas metros, Sept 2026
- Metro annual job growth: 0.9% — 500 jobs added, below TX's 1.1% rate
- Texas manufacturing wage growth: 4.8% — Strongest since Dec 2023, outpaces Sherman activity
- Lab Technician advertised pay (metro): $45,314 — Stable vs national $47,402 (declining moderately)
Key takeaways
Sherman's labor market is stable, not specialized.
4.4% unemployment and flat monthly job growth signal a steady general labor market, but the metro's employer base (Tyson, TI, Sherman ISD) offers no evidence of a maturing life sciences cluster. Leaders should treat Sherman as a cost-efficient operations location, not a talent source for scientific or regulatory roles.
Lab Technician pay is flat while national rates soften further.
Metro lab technician pay held stable at $45,314 against a national median of $47,402 that is declining moderately. Local stability without downward pressure may suggest employers are holding the line on technician pay even as national demand softens, a signal worth tracking for retention risk if nearby metros pull ahead.
Texas manufacturing wage momentum bypasses Sherman so far.
Statewide manufacturing wages grew 4.8% over the past year, the fastest pace since 2023, driven largely by Houston-area biomanufacturing expansion. Sherman's flat annual job growth (0.9%) suggests this wage acceleration has not yet reached the metro, creating a widening compensation gap for any manufacturing or quality roles competing against Houston-based CDMO and biologics investment.
Regulatory scarcity nationally raises the stakes for remote hiring locally.
VP Regulatory Affairs compensation nationally ranges $320K–$580K amid acute talent scarcity, a premium Sherman-based organizations cannot realistically fund through local-only recruiting. Current conditions suggest building remote-eligible regulatory and medical affairs roles anchored to DFW or national talent pools rather than assuming a local hire is achievable at competitive cost.
Median advertised pay by role — Sherman-Denison, TX MSA
| Role | 25th percentile | Median advertised pay | 75th percentile | Metro trend | National median |
|---|---|---|---|---|---|
| Research Scientist * | $84,986 | $125,310 | $136,499 | Significant increase | $131,354 |
| Clinical Research Associate * | $58,220 | $81,374 | $98,325 | Significant increase | $90,956 |
| Lab Technician * | $37,740 | $45,314 | $49,226 | Stable | $47,402 |
| Regulatory Affairs Specialist * | $70,793 | $95,949 | $116,373 | Moderate decline | $104,000 |
| Clinical Data Manager * | $96,493 | $122,953 | $136,780 | Stable | $123,031 |
| Biostatistician * | $104,135 | $141,493 | $163,775 | Significant increase | $133,322 |
| Validation Engineer * | $82,458 | $105,350 | $113,458 | Significant increase | $108,377 |
* State-level figure shown where metro postings were too few.
WageScape's median is calibrated to correct for spurious low-value postings (reported as the 60th percentile of raw advertised pay). Download: CSV · JSON
Local market conditions
Sherman-Denison's 4.4% unemployment rate and flat month-over-month job growth through September 2026 reflect a metro economy still anchored by Texas Instruments and Tyson rather than a dedicated life sciences base, leaving specialized scientific talent largely dependent on Dallas-Fort Worth commuting or relocation. Statewide manufacturing wage growth of 4.8% and continued biomanufacturing investment in Houston and the broader Texas corridor are pulling skilled operators and quality personnel toward larger hubs, widening the gap between what Sherman-based employers can offer and what regional competitors advertise.
What it means
Thin local labor supply for regulated, credential-heavy roles means Sherman-area life sciences operations — whether standalone sites or satellite functions of larger Texas-based organizations — face longer time-to-fill and greater reliance on relocation incentives or remote/hybrid regulatory and quality staffing than peers in Houston or Dallas. With Texas pharma employer growth running at 56.2% since 2019 concentrated in major metros, build-vs-outsource calculus for Sherman-based manufacturing or QC functions increasingly favors CDMO partnerships over local hiring unless roles can be filled from the DFW commuter shed. Consider evaluating whether Sherman-based R&D, quality, or regulatory headcount should be reclassified as hybrid-eligible to tap DFW's deeper specialized talent pool rather than competing purely on local advertised pay.
Looking ahead
Worth watching: Grayson County's unemployment rate (4.6%) sits slightly above the metro average, suggesting pockets of softer labor conditions outside Sherman proper. Watch whether this spread widens, which could ease sourcing for support and technician-level roles even as specialized talent remains scarce.
Emerging pressure point: Houston's $6.5B Eli Lilly and $2.3B Bristol Myers Squibb manufacturing buildouts are expected to absorb skilled operators and quality specialists statewide over the next several quarters. Sherman-area employers competing for the same credentialed workforce should expect increased counteroffer activity and slower fill rates for manufacturing and QC roles.
Potential inflection point: Texas Workforce Commission's modest 100-job metro gain from August to September could tip either direction depending on whether TI or Tyson announce expansion or contraction plans. Any material shift in these anchor employers would reshape local wage comparisons life sciences employers use for support and technical staff.
Early indicator: National biopharma layoffs (BioMarin, Bristol Myers Squibb) are concentrated in consolidation functions, not execution-critical roles, with 64% of organizations still actively recruiting. Watch whether any displaced regulatory or quality talent becomes available to the broader DFW commuter pool feeding Sherman-area employers.
Methodology
Advertised pay from active employer job postings, not survey data. WageScape's median is calibrated to correct for spurious low-value postings: distribution analysis shows roughly the lowest 10% of raw values are erroneous entries, so the reported median is the 60th percentile of raw advertised pay. WageScape observes 98% of U.S. job openings daily.
Free to read and cite with attribution to WageScape. Terms of use.